Gabelli Funds’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Gabelli Funds’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,050	Closed	-$3.52K	–	1127
2024 Q4	$3.52K	Hold	27,050	–	–	﹤0.01%	1081
2024 Q3	$2.95K	Hold	27,050	–	–	﹤0.01%	1077
2024 Q2	$2.71K	Hold	27,050	–	–	﹤0.01%	1078
2024 Q1	$4.05K	Hold	27,050	–	–	﹤0.01%	1078
2023 Q4	$4.05K	Hold	27,050	–	–	﹤0.01%	1085
2023 Q3	$6.22K	Hold	27,050	–	–	﹤0.01%	1097
2023 Q2	$5.17K	Buy	+27,050	New	+$4.71K	﹤0.01%	1098

Gabelli Funds's BLACR Position: Q1 2025 in Review

Gabelli Funds sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 27,050 shares — an estimated $3.52K sold.

Gabelli Funds first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $6.22K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Gabelli Funds reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Gabelli Funds sold 27,050 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $3.52K.
Gabelli Funds first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
Gabelli Funds's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $6.22K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Gabelli Funds's 13F filing for Q1 2025, filed 14 May 2025.